Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2021 | Frontline treatment strategies in AML

Andrius Žučenka • 7 Jun 2021
EHA 2021
Acute Myeloid Leukemia Leukemia Antibodies CPX-351 Cytarabine Gemtuzumab ozogamicin Midostaurin Venetoclax

Andrius Zucenka, MD, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania, gives an overview of frontline treatment strategies for unfit patients with acute myeloid leukemia (AML), highlighting the addition of venetoclax to standard hypomethylating agents or low-dose cytarabine. For fit patients, Dr Zucenka comments on standard induction with midostaurin, as well as the potential roles of CPX-351 and gemtuzumab in the future. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

More from Andrius Žučenka

2:18
VEN-AZA versus intensive chemotherapy as bridging therapy in patients with MDS
Andrius Žučenka • 8 Dec 2023
3:52
Maintenance therapy with revumenib following alloSCT in KMT2Ar and NPM1-mutated acute leukemias
Andrius Žučenka • 8 Dec 2023
2:27
Challenges with managing the high rates of infections seen in patients with AML
Andrius Žučenka • 8 Dec 2023
2:12
Approaching patients with FLT3-mutated AML who are ineligible for high-intensity chemotherapy
Andrius Žučenka • 8 Dec 2023

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals